Da Volterra joins the IMI-Funded European Consortium COMBACTE-NET to accelerate the development of therapeutic solutions combating antibiotic resistance and bacterial infections
Da Volterra announces today its participation in the European Consortium COMBACTE-NET (Combatting Bacterial Resistance in Europe) alongside MedImmune, the global biologics research and development arm of AstraZeneca, and The Medicines Company.
Within the framework of this initiative, Da Volterra is launching an epidemiological study on 1.000 patients recruited in 30 European clinical centers (Netherlands, Germany, Greece, Spain, Romania, France). These patients over 50 years of age, receiving antibiotic treatment, will be followed over a 3 month period to detect any occurrence of Clostridium difficile infections following antibiotic treatment. The objective of this study consists of the detailed analysis of the risk factors for Clostridium difficile infections and in so discerning the populations for which the prevention of this pathology will be the most effective. In effect, Da Volterra is developing a therapeutic solution, designated under the code DAV132, which aims at preventing Clostridium difficile infections in at high-risk patients.
More information available in the press release from Da Volterra.